Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma

To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors. The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen recept...

Full description

Saved in:
Bibliographic Details
Published inJournal of gynecologic oncology Vol. 29; no. 3; pp. e30 - 11
Main Authors Baek, Min-Hyun, Park, Jeong-Yeol, Park, Yangsoon, Kim, Kyu-Rae, Kim, Dae-Yeon, Suh, Dae-Shik, Kim, Jong-Hyeok, Kim, Yong-Man, Kim, Young-Tak, Nam, Joo-Hyun
Format Journal Article
LanguageEnglish
Published Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 01.05.2018
대한부인종양학회
Subjects
Adult
Aged
Biomarkers, Tumor - analysis
Disease-Free Survival
Female
Humans
Immunohistochemistry
Leiomyosarcoma - chemistry
Leiomyosarcoma - mortality
Leiomyosarcoma - pathology
Middle Aged
Neoplasm Staging
Original
Prognosis
Receptors, Androgen - analysis
Receptors, Progesterone - analysis
Uterine Neoplasms - chemistry
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
산부인과학
Immunohistochemistry
Androgen Receptor
Leiomyosarcoma
Online AccessGet full text
ISSN2005-0380
2005-0399
2005-0399
DOI10.3802/jgo.2018.29.e30

Cover

Abstract To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors. The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray. In total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2-28.4 and OR=0.2; 95% CI=0.05-0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR. AR can be a potential prognostic biomarker in uterine leiomyosarcoma.
AbstractList Objective: To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors. Methods: The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray. Results: In total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2–28.4 and OR=0.2; 95% CI=0.05–0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR. Conclusion: AR can be a potential prognostic biomarker in uterine leiomyosarcoma. KCI Citation Count: 1
To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors.OBJECTIVETo investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors.The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray.METHODSThe medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray.In total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2-28.4 and OR=0.2; 95% CI=0.05-0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR.RESULTSIn total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2-28.4 and OR=0.2; 95% CI=0.05-0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR.AR can be a potential prognostic biomarker in uterine leiomyosarcoma.CONCLUSIONAR can be a potential prognostic biomarker in uterine leiomyosarcoma.
To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other hormone receptors. The medical records and paraffin blocks of 42 patients were reviewed. The immunohistochemical expression of AR, estrogen receptor (ER), progesterone receptor (PR), gonadotropin releasing hormone (GnRH), and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) were assessed using tissue microarray. In total, AR expression was observed in 11 patients (26.2%). International Federation of Gynecology and Obstetrics (FIGO) stage and AR were independent factors for disease-free survival (DFS) in multivariate regression analysis (odds ratio [OR]=5.8; 95% confidence interval [CI]=1.2-28.4 and OR=0.2; 95% CI=0.05-0.90; p=0.029 and 0.032, respectively). There were no deaths in the AR expression group, whereas the 5-year overall survival (OS) was 54.8% in the no expression group (p=0.014). Co-expression of ER and/or PR with AR was associated with significantly better 5-year DFS and OS than those with negative AR (72.7% vs. 28.6% and 100% vs. 64.3%; p=0.020 and 0.036, respectively). AR may be an independent prognostic marker regardless of ER/PR. AR can be a potential prognostic biomarker in uterine leiomyosarcoma.
Author Kim, Yong-Man
Nam, Joo-Hyun
Kim, Young-Tak
Kim, Dae-Yeon
Park, Yangsoon
Baek, Min-Hyun
Park, Jeong-Yeol
Kim, Kyu-Rae
Suh, Dae-Shik
Kim, Jong-Hyeok
AuthorAffiliation 2 Department of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea
1 Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
3 Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
AuthorAffiliation_xml – name: 3 Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– name: 1 Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– name: 2 Department of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea
Author_xml – sequence: 1
  givenname: Min-Hyun
  orcidid: 0000-0003-0423-9038
  surname: Baek
  fullname: Baek, Min-Hyun
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea., Department of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea
– sequence: 2
  givenname: Jeong-Yeol
  orcidid: 0000-0003-2475-7123
  surname: Park
  fullname: Park, Jeong-Yeol
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 3
  givenname: Yangsoon
  surname: Park
  fullname: Park, Yangsoon
  organization: Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 4
  givenname: Kyu-Rae
  surname: Kim
  fullname: Kim, Kyu-Rae
  organization: Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 5
  givenname: Dae-Yeon
  orcidid: 0000-0002-8068-3475
  surname: Kim
  fullname: Kim, Dae-Yeon
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 6
  givenname: Dae-Shik
  surname: Suh
  fullname: Suh, Dae-Shik
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 7
  givenname: Jong-Hyeok
  surname: Kim
  fullname: Kim, Jong-Hyeok
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 8
  givenname: Yong-Man
  surname: Kim
  fullname: Kim, Yong-Man
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 9
  givenname: Young-Tak
  surname: Kim
  fullname: Kim, Young-Tak
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
– sequence: 10
  givenname: Joo-Hyun
  surname: Nam
  fullname: Nam, Joo-Hyun
  organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29533018$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002344026$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqFUUtv1DAQtlARfcCZG8qRHnY7sddJfEFaVS1UqoSE2huSNetMtu5m7WA7oP33ddhSHgd6Gsvfy_P5mB0474ixtyXMRQP87H7t5xzKZs7VnAS8YEccQM5AKHXwdG7gkB3HeA9Q1dDwV-yQKylElh2xr0vXBr8mVwQyNCQfCowFFkO-dD4ma4qV9VsMG8qIa4t0RwEHGickYVhTKqwrxkTBOip6yuSdjxhMFr1mLzvsI715nCfs9vLi5vzT7Przx6vz5fXMLHidZpLLhVGci7pqCboF1lAhtJ3kpaH8zkoA1o3B1lQKBVBHWNe44gtBgsp6JU7Y6d7XhU5vjNUe7c-59noT9PLLzZXOPlBWVebCnju6AXc_sO_1EGxecKdL0FOpOpeqp1I1VzqXmiUf9pJhXG2pNeRSwN-yKexvxNm7HP1dS8WBl3U2eP9oEPy3kWLSWxsN9T068mOcwoQsJVQqU9_9mfUU8uvHMkHuCSb4GAN12tiEyfop2vb_WeLsH91zaz8AMBe8ig
CitedBy_id crossref_primary_10_6061_clinics_2021_e2324
crossref_primary_10_1002_cncr_34372
crossref_primary_10_3390_cancers14040921
crossref_primary_10_3390_ijms20051136
crossref_primary_10_1016_j_jogoh_2019_101631
crossref_primary_10_1158_1541_7786_MCR_20_0197
crossref_primary_10_3390_cancers14061561
crossref_primary_10_33667_2078_5631_2020_20_49_53
crossref_primary_10_1016_j_ygyno_2022_09_024
crossref_primary_10_17650_2219_4614_2024_16_1_11_24
crossref_primary_10_3389_fonc_2024_1343533
crossref_primary_10_3390_biomedicines10102567
Cites_doi 10.1097/IGC.0000000000000370
10.1002/cncr.28476
10.1097/PGP.0000000000000355
10.1016/S0140-6736(12)60651-5
10.1186/2045-3329-4-5
10.1001/jama.1997.03540350075038
10.1002/cncr.2820710440
10.1016/j.biocel.2009.11.013
10.1016/j.ygyno.2009.09.023
10.1111/j.1365-2559.2009.03231.x
10.1016/j.ygyno.2009.10.064
10.1016/j.ygyno.2005.05.019
10.1016/j.ijgo.2008.12.008
10.3802/jgo.2015.26.3.214
10.1002/cncr.20521
10.1245/s10434-012-2834-0
10.1016/j.ygyno.2009.09.011
10.3322/caac.21332
10.1200/JCO.2014.58.3781
10.1016/j.ygyno.2011.11.009
10.1097/IGC.0b013e31825b7de8
10.1097/PGP.0000000000000353
10.1016/j.ygyno.2009.08.014
10.3802/jgo.2013.24.4.298
10.4143/crt.2016.092
10.1016/j.maturitas.2012.01.021
10.1016/j.ygyno.2012.11.009
10.1038/bjc.2016.16
10.18632/oncotarget.10334
10.1200/JCO.2008.19.8366
10.1073/pnas.0506736102
10.1007/s13277-010-0138-1
ContentType Journal Article
Copyright Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology 2018 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology
Copyright_xml – notice: Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
– notice: Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology 2018 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
ACYCR
DOI 10.3802/jgo.2018.29.e30
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-0399
EndPage 11
ExternalDocumentID oai_kci_go_kr_ARTI_3300166
10.3802/jgo.2018.29.e30
PMC5920217
29533018
10_3802_jgo_2018_29_e30
Genre Journal Article
GroupedDBID 29K
2WC
5-W
53G
5GY
8JR
8XY
9ZL
AAKDD
AAYXX
ABDBF
ACUHS
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
D-I
DIK
DU5
E3Z
EBD
EF.
F5P
GROUPED_DOAJ
HYE
HZB
OK1
RPM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
ACYCR
M~E
ID FETCH-LOGICAL-c427t-5254c922376de0f4a706a0df521ce330630a78cadc69a30efea77ab243e3e17b3
IEDL.DBID UNPAY
ISSN 2005-0380
2005-0399
IngestDate Tue Nov 21 21:39:43 EST 2023
Sun Oct 26 04:12:47 EDT 2025
Thu Aug 21 14:10:54 EDT 2025
Fri Jul 11 09:08:14 EDT 2025
Mon Jul 21 05:48:08 EDT 2025
Tue Jul 01 02:37:30 EDT 2025
Thu Apr 24 22:59:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Immunohistochemistry
Androgen Receptor
Leiomyosarcoma
Language English
License https://creativecommons.org/licenses/by-nc/4.0
Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c427t-5254c922376de0f4a706a0df521ce330630a78cadc69a30efea77ab243e3e17b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
https://doi.org/10.3802/jgo.2018.29.e30
ORCID 0000-0002-8068-3475
0000-0003-2475-7123
0000-0003-0423-9038
OpenAccessLink https://proxy.k.utb.cz/login?url=https://doi.org/10.3802/jgo.2018.29.e30
PMID 29533018
PQID 2013515069
PQPubID 23479
PageCount 11
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_3300166
unpaywall_primary_10_3802_jgo_2018_29_e30
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5920217
proquest_miscellaneous_2013515069
pubmed_primary_29533018
crossref_citationtrail_10_3802_jgo_2018_29_e30
crossref_primary_10_3802_jgo_2018_29_e30
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-05-01
PublicationDateYYYYMMDD 2018-05-01
PublicationDate_xml – month: 05
  year: 2018
  text: 2018-05-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of gynecologic oncology
PublicationTitleAlternate J Gynecol Oncol
PublicationYear 2018
Publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
대한부인종양학회
Publisher_xml – name: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
– name: 대한부인종양학회
References Lim (10.3802/jgo.2018.29.e30_ref2) 2013; 24
Prat (10.3802/jgo.2018.29.e30_ref23) 2009; 104
Yamazaki (10.3802/jgo.2018.29.e30_ref32) 2015; 26
O'Cearbhaill (10.3802/jgo.2018.29.e30_ref15) 2010; 116
Koivisto-Korander (10.3802/jgo.2018.29.e30_ref4) 2012; 72
Koivisto-Korander (10.3802/jgo.2018.29.e30_ref18) 2011; 32
van der Graaf (10.3802/jgo.2018.29.e30_ref6) 2012; 379
Lusby (10.3802/jgo.2018.29.e30_ref30) 2013; 20
Tangen (10.3802/jgo.2018.29.e30_ref29) 2016; 7
Major (10.3802/jgo.2018.29.e30_ref25) 1993; 71
Hensley (10.3802/jgo.2018.29.e30_ref8) 2009; 115
Siegel (10.3802/jgo.2018.29.e30_ref1) 2016; 66
Jung (10.3802/jgo.2018.29.e30_ref3) 2016; 48
Abeler (10.3802/jgo.2018.29.e30_ref24) 2009; 54
Kamal (10.3802/jgo.2018.29.e30_ref28) 2016; 114
Leitao (10.3802/jgo.2018.29.e30_ref19) 2004; 101
Roy (10.3802/jgo.2018.29.e30_ref20) 2017; 36
Bennett (10.3802/jgo.2018.29.e30_ref26) 2010; 42
Lim (10.3802/jgo.2018.29.e30_ref10) 2013; 128
Shiina (10.3802/jgo.2018.29.e30_ref27) 2006; 103
George (10.3802/jgo.2018.29.e30_ref17) 2014; 120
(10.3802/jgo.2018.29.e30_ref22) 1997; 277
Ioffe (10.3802/jgo.2018.29.e30_ref12) 2009; 115
Leitao (10.3802/jgo.2018.29.e30_ref13) 2012; 124
Altman (10.3802/jgo.2018.29.e30_ref16) 2012; 22
Thanopoulou (10.3802/jgo.2018.29.e30_ref31) 2014; 4
Akhan (10.3802/jgo.2018.29.e30_ref11) 2005; 99
D'Angelo (10.3802/jgo.2018.29.e30_ref5) 2010; 116
Zivanovic (10.3802/jgo.2018.29.e30_ref9) 2009; 27
Hensley (10.3802/jgo.2018.29.e30_ref7) 2015; 33
Garcia (10.3802/jgo.2018.29.e30_ref14) 2015; 25
Mahdi (10.3802/jgo.2018.29.e30_ref21) 2017; 36
References_xml – volume: 25
  start-page: 622
  year: 2015
  ident: 10.3802/jgo.2018.29.e30_ref14
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0000000000000370
– volume: 120
  start-page: 738
  year: 2014
  ident: 10.3802/jgo.2018.29.e30_ref17
  publication-title: Cancer
  doi: 10.1002/cncr.28476
– volume: 36
  start-page: 405
  year: 2017
  ident: 10.3802/jgo.2018.29.e30_ref21
  publication-title: Int J Gynecol Pathol
  doi: 10.1097/PGP.0000000000000355
– volume: 379
  start-page: 1879
  year: 2012
  ident: 10.3802/jgo.2018.29.e30_ref6
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60651-5
– volume: 4
  start-page: 5
  year: 2014
  ident: 10.3802/jgo.2018.29.e30_ref31
  publication-title: Clin Sarcoma Res
  doi: 10.1186/2045-3329-4-5
– volume: 277
  start-page: 925
  year: 1997
  ident: 10.3802/jgo.2018.29.e30_ref22
  publication-title: JAMA
  doi: 10.1001/jama.1997.03540350075038
– volume: 71
  start-page: 1702
  year: 1993
  ident: 10.3802/jgo.2018.29.e30_ref25
  publication-title: Cancer
  doi: 10.1002/cncr.2820710440
– volume: 42
  start-page: 813
  year: 2010
  ident: 10.3802/jgo.2018.29.e30_ref26
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2009.11.013
– volume: 116
  start-page: 131
  year: 2010
  ident: 10.3802/jgo.2018.29.e30_ref5
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.09.023
– volume: 54
  start-page: 355
  year: 2009
  ident: 10.3802/jgo.2018.29.e30_ref24
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2009.03231.x
– volume: 116
  start-page: 424
  year: 2010
  ident: 10.3802/jgo.2018.29.e30_ref15
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.10.064
– volume: 99
  start-page: 36
  year: 2005
  ident: 10.3802/jgo.2018.29.e30_ref11
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2005.05.019
– volume: 104
  start-page: 177
  year: 2009
  ident: 10.3802/jgo.2018.29.e30_ref23
  publication-title: Int J Gynaecol Obstet
  doi: 10.1016/j.ijgo.2008.12.008
– volume: 26
  start-page: 214
  year: 2015
  ident: 10.3802/jgo.2018.29.e30_ref32
  publication-title: J Gynecol Oncol
  doi: 10.3802/jgo.2015.26.3.214
– volume: 101
  start-page: 1455
  year: 2004
  ident: 10.3802/jgo.2018.29.e30_ref19
  publication-title: Cancer
  doi: 10.1002/cncr.20521
– volume: 20
  start-page: 2364
  year: 2013
  ident: 10.3802/jgo.2018.29.e30_ref30
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-012-2834-0
– volume: 115
  start-page: 460
  year: 2009
  ident: 10.3802/jgo.2018.29.e30_ref8
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.09.011
– volume: 66
  start-page: 7
  year: 2016
  ident: 10.3802/jgo.2018.29.e30_ref1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21332
– volume: 33
  start-page: 1180
  year: 2015
  ident: 10.3802/jgo.2018.29.e30_ref7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.58.3781
– volume: 124
  start-page: 558
  year: 2012
  ident: 10.3802/jgo.2018.29.e30_ref13
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2011.11.009
– volume: 22
  start-page: 1006
  year: 2012
  ident: 10.3802/jgo.2018.29.e30_ref16
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0b013e31825b7de8
– volume: 36
  start-page: 420
  year: 2017
  ident: 10.3802/jgo.2018.29.e30_ref20
  publication-title: Int J Gynecol Pathol
  doi: 10.1097/PGP.0000000000000353
– volume: 115
  start-page: 466
  year: 2009
  ident: 10.3802/jgo.2018.29.e30_ref12
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.08.014
– volume: 24
  start-page: 298
  year: 2013
  ident: 10.3802/jgo.2018.29.e30_ref2
  publication-title: J Gynecol Oncol
  doi: 10.3802/jgo.2013.24.4.298
– volume: 48
  start-page: 451
  year: 2016
  ident: 10.3802/jgo.2018.29.e30_ref3
  publication-title: Cancer Res Treat
  doi: 10.4143/crt.2016.092
– volume: 72
  start-page: 56
  year: 2012
  ident: 10.3802/jgo.2018.29.e30_ref4
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2012.01.021
– volume: 128
  start-page: 322
  year: 2013
  ident: 10.3802/jgo.2018.29.e30_ref10
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2012.11.009
– volume: 114
  start-page: 688
  year: 2016
  ident: 10.3802/jgo.2018.29.e30_ref28
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2016.16
– volume: 7
  start-page: 49289
  year: 2016
  ident: 10.3802/jgo.2018.29.e30_ref29
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10334
– volume: 27
  start-page: 2066
  year: 2009
  ident: 10.3802/jgo.2018.29.e30_ref9
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.8366
– volume: 103
  start-page: 224
  year: 2006
  ident: 10.3802/jgo.2018.29.e30_ref27
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0506736102
– volume: 32
  start-page: 451
  year: 2011
  ident: 10.3802/jgo.2018.29.e30_ref18
  publication-title: Tumour Biol
  doi: 10.1007/s13277-010-0138-1
SSID ssj0067082
Score 2.1695464
Snippet To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with other...
Objective: To investigate the expression of androgen receptor (AR) and its correlation with disease status and survival outcome in uterine leiomyosarcoma with...
SourceID nrf
unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e30
SubjectTerms Adult
Aged
Biomarkers, Tumor - analysis
Disease-Free Survival
Female
Humans
Immunohistochemistry
Leiomyosarcoma - chemistry
Leiomyosarcoma - mortality
Leiomyosarcoma - pathology
Middle Aged
Neoplasm Staging
Original
Prognosis
Receptors, Androgen - analysis
Receptors, Progesterone - analysis
Uterine Neoplasms - chemistry
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
산부인과학
Title Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma
URI https://www.ncbi.nlm.nih.gov/pubmed/29533018
https://www.proquest.com/docview/2013515069
https://pubmed.ncbi.nlm.nih.gov/PMC5920217
https://doi.org/10.3802/jgo.2018.29.e30
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002344026
UnpaywallVersion publishedVersion
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Gynecologic Oncology, 2018, 29(3), , pp.1-11
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2005-0399
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067082
  issn: 2005-0399
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2005-0399
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067082
  issn: 2005-0399
  databaseCode: ABDBF
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2005-0399
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067082
  issn: 2005-0399
  databaseCode: DIK
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2005-0399
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067082
  issn: 2005-0399
  databaseCode: 5-W
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2005-0399
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067082
  issn: 2005-0399
  databaseCode: RPM
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB5BVwIuvB_hsTKIAxwSUjvP4wqxKki74kClRUKyxo6zlFZO1YfQ8uuZSdKqhUXAKYk8tmN7HM_En78BeBljLJEM8TAzeRImqYtDTNGExpT0oSSDAtsoESen2WicfDhLz3qSJD4Ls7N_r4pYvvl2zif0hkUky8gp8s0PspSM7gEcjE8_Hn3m0HHMpRmrNkZaf1-WHYnPZSXsrT9X_aK-zLT8HSF5fe3nePEdZ7Od5ef4Fow2L96hTqbRemUi--MXTsd_aNltuNmboOKo05k7cMX5u3DtpN9kvwdfGOTYkGIJ-hq6OTnlApcCBUO5fMO8zoIP7TOuh1J8JXbOcIkOWS4mXnCsCCpPzBwJXzRLmlGU6T6Mj999ejsK-yAMoU1kviJHNU1sKRk8U7m4TjCPM4yrmpZ965Riyi7MC4uVzUpUsasd5jkamSin3DA36gEMfOPdIxASVW0M2ZSFtInCtGDfqiKPMJF26GwdQLQZGm17hnIOlDHT5Klwn2nqM819pmWpqc8CeLXNMO_IOf4s-oLGWk_tRDOhNl9JYLrQ5Da819QOMn2zAJ5vVEHTLOOtE_SuWS-5JJUyGWMZwMNONbY1yhahOywCyPeUZivAFe6n-MnXlsk7LSX7hAG83qrX3xry-D9kn8ANfurwmU9hsFqs3TOyoVbmsP33cNjPop-EZhcv
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9BJ8FeGN8LDGQQD_CQkNr5fJymTQVpEw9UGhKSdXYcKK2cqh9C46_nrkmrFoaApyTy2Y7ts30n__w7gFcxxhLJEA8zkydhkro4xBRNaExJCyUZFLiKEnF-kQ2GyfvL9LIjSeK7MFvn96qI5dtvX_iGXr-IZBk5Rb75XpaS0d2DveHFh-NPHDqOuTRjtYqR1r2XZUvic10JO_vPTT-rrzMtf0dI3l76KV59x8lka_s5O4DB-sdb1Mk4Wi5MZH_8wun4Dy27C3c6E1QctzpzD244fx9unXeH7A_gM4McG1IsQauhm5JTLnAuUDCUyzfM6yz40j7jeijFV2LrDpdokeVi5AXHiqDyxMSR8FUzpxlFmR7C8Oz048kg7IIwhDaR-YIc1TSxpWTwTOXiOsE8zjCuatr2rVOKKbswLyxWNitRxa52mOdoZKKccv3cqEfQ8413hyAkqtoYsikLaROFacG-VUUeYSJt39k6gGg9NNp2DOUcKGOiyVPhPtPUZ5r7TMtSU58F8HqTYdqSc_xZ9CWNtR7bkWZCbX6SwHimyW14p6kdZPpmAbxYq4KmWcZHJ-hds5xzSSplMsYygMetamxqlCuEbr8IIN9Rmo0AV7ib4kdfV0zeaSnZJwzgzUa9_taQJ_8h-xT2-avFZx5BbzFbumdkQy3M827-_AT_CBY6
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Androgen+receptor+as+a+prognostic+biomarker+and+therapeutic+target+in+uterine+leiomyosarcoma&rft.jtitle=Journal+of+gynecologic+oncology&rft.au=Baek%2C+Min-Hyun&rft.au=Park%2C+Jeong-Yeol&rft.au=Park%2C+Yangsoon&rft.au=Kim%2C+Kyu-Rae&rft.date=2018-05-01&rft.issn=2005-0380&rft.eissn=2005-0399&rft.volume=29&rft.issue=3&rft_id=info:doi/10.3802%2Fjgo.2018.29.e30&rft.externalDBID=n%2Fa&rft.externalDocID=10_3802_jgo_2018_29_e30
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-0380&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-0380&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-0380&client=summon